Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
| Autor: | Eugene R. Bleecker, William W. Busse, Lucy Frith, Leslie Andersen, Jessica Lim, Jan Lötvall, Ashley Woodcock, Paul M. O'Byrne, Eric D. Bateman, Loretta Jacques |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Risk Pulmonary and Respiratory Medicine medicine.medical_specialty Evening Adolescent Exacerbation medicine.drug_class Asthma Pharmacology Chlorobenzenes Fluticasone propionate chemistry.chemical_compound Double-Blind Method Forced Expiratory Volume Internal medicine Administration Inhalation medicine Humans Anti-Asthmatic Agents Child Glucocorticoids Benzyl Alcohols Asthma business.industry medicine.disease Fluticasone furoate/vilanterol respiratory tract diseases Androstadienes Treatment Outcome chemistry Tolerability Anesthesia Corticosteroid Drug Therapy Combination Female Vilanterol business medicine.drug |
| Zdroj: | Thorax |
| ISSN: | 1468-3296 0040-6376 |
| DOI: | 10.1136/thoraxjnl-2013-203600 |
| Popis: | Background Combination therapy with an inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) is recommended for patients with asthma symptomatic on ICS alone. However, there is ongoing debate regarding the risk-benefit ratio of using LABA in asthma. Objective To evaluate the effect of the addition of a novel LABA, vilanterol (VI), to a once-daily ICS, fluticasone furoate (FF), on the risk of severe asthma exacerbations in patients with uncontrolled asthma. Methods This randomised double-blind comparative study of variable duration (≥24–78 weeks) was designed to finish after 330 events (each patient's first on-treatment severe asthma exacerbation). 2019 patients with asthma aged ≥12 years with ≥1 recorded exacerbation within 1 year were randomised and received FF/VI 100/25 μg or FF 100 μg, administered once daily in the evening. The primary endpoint was time to first severe exacerbation; secondary endpoints were rate of severe asthma exacerbations per patient per year and change in trough evening forced expiratory volume in 1 s (FEV1) from baseline. Results Compared with FF, FF/VI delayed the time to first severe exacerbation (HR 0.795, 95% CI 0.642 to 0.985) and reduced the annualised rate of severe exacerbations (rate reduction 25%, 95% CI 5% to 40%). Significantly greater improvements in trough FEV1 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|